18F-DCFPyL PET-CT显像对退伍军人侵袭性前列腺癌初始分期、放疗及全身治疗推荐的影响
本研究为退伍军人事务部(大洛杉矶地区)前瞻性单中心单臂显像试验,纳入100例既往未治疗的前列腺癌退伍军人,在常规影像基础上加做18F-DCFPyL PET-CT。初判无转移者中19/84(23%)上调为M1,初判M1者中8/16(50%)下调为M0;39/100(39%)预设治疗推荐发生改变。
要点
- 初判无转移患者中23%(19/84)经18F-DCFPyL PET-CT上调为M1。
- 初判M1患者中50%(8/16)经该显像下调为M0。
- 39/100(39%)预设治疗推荐改变,其中放疗体积/剂量改变39/100(39%),启动阿比特龙22/100(22%)。
诊断标准与关键数值
- 初判无转移患者中19/84(23%)经18F-DCFPyL PET-CT上调为M1期。
- 初判M1患者中8/16(50%)经18F-DCFPyL PET-CT下调为M0期。
- 总体39/100(39%)预设治疗推荐发生改变,其中放疗体积/剂量改变39/100(39%),启动阿比特龙22/100(22%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Our purpose was to study the effect of 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyL) positron emission tomography (PET)-computed tomography (CT) on staging/treatment recommendations of previously untreated prostate cancer. We report here results of a prospective single center single arm imaging trial within Veterans Affairs (Greater Los Angeles): the frequency of patients upstaged to M1 disease (primary endpoint) and the frequency of patients with change in treatment recommendations (secondary endpoint). This is the first report of prostate-specific membrane antigen PET-CT exclusive to U.S. veterans.
METHODS AND MATERIALS: Veterans with Gleason ≥4 + 3, clinical stage ≥T2c, or prostate-specific antigen >10 ng/mL were eligible. Patients underwent conventional imaging (99mTc-methyl diphosphonate bone scan or 18F-NaF PET-CT; and pelvic CT or pelvic magnetic resonance imaging) in addition to 18F-DCFPyL PET-CT. The effect of 18F-DCFPyL PET-CT on treatment change was determined by applying prespecified treatment recommendations based on National Comprehensive Cancer Network guidelines and modern clinical practice.
RESULTS: One hundred patients underwent 18F-DCFPyL PET-CT. Nineteen out of 84 (23%) patients initially thought to be nonmetastatic were upstaged to M1; 8/16 (50%) patients initially thought to have M1 disease were downstaged to M0. In total, 39/100 (39%) had a change in prespecified treatment recommendations, including change of radiation therapy volume/dose in 39/100 (39%) and starting abiraterone in 22/100 (22%).
CONCLUSIONS: Incorporation of 18F-DCFPyL PET-CT into the initial conventional imaging workup for prostate cancer can substantially affect staging/treatment recommendations.
引用
- Parikh NR, Tsai S, Bennett C, et al. The Impact of 18F-DCFPyL PET-CT Imaging on Initial Staging, Radiation, and Systemic Therapy Treatment Recommendations for Veterans With Aggressive Prostate Cancer. Adv Radiat Oncol. 2020. PMID: 33305100. doi:10.1016/j.adro.2020.08.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。